Introduction
============

Colorectal cancer (CRC) has become a major cause of morbidity and mortality worldwide.[@b1-ott-9-5897] Currently, the newly diagnosed cases in the world are over one million per year.[@b2-ott-9-5897] Radical resection is the main treatment for CRC, but metastasis or recurrence is common in which liver metastasis accounted for 83% of the cases.[@b3-ott-9-5897] Therefore, prevention of liver metastases can be expected to improve most effectively the prognosis of patients with advanced CRC. Multiple trials over the past decades have shown that hepatic arterial infusion chemotherapy (HAIC) is an effective treatment for liver metastases from CRC with superior response rates (RRs) compared with systemic or portal vein infusion chemotherapy.[@b4-ott-9-5897] Moreover, a pilot study proved that preventive adjuvant HAIC with 5-fluorouracil (5-FU) could effectively prevent metachronous liver metastasis from CRC after curative resection compared with nontreated patients.[@b5-ott-9-5897] However, it is still unclear whether prophylactic adjuvant HAIC is superior to systemic chemotherapy in the prevention of liver metastasis.

Oxaliplatin (OXA) is a new platinum compound with significant activity in CRC. For patients with CRC, adding OXA to 5-FU/folinic acid (FA) has produced greater RRs and overall survival (OS).[@b6-ott-9-5897],[@b7-ott-9-5897] In a rabbit tumor model, intra-arterial (ia) hepatic OXA has shown a significant pharmacokinetic advantage compared with intravenous (iv) infusion.[@b8-ott-9-5897] Several Phase I and II studies of HAI with OXA have been published to date. Tolerability and efficacy in heavily pretreated patients have been demonstrated; in particular, a liver extraction of OXA above 50% with minimal systemic concentration and toxicity has been reported.[@b9-ott-9-5897],[@b10-ott-9-5897] The aim of this study was to determine the efficacy of OXA/FA/5-FU administrated by hepatic arterial infusion (HAI) in patients with stage III CRC after curative resection.

Methodology
===========

Patients
--------

A total of 287 cases of stage III CRC patients who underwent radical resection in the First People's Hospital affiliated to Huzhou University Medical College between 2002 and 2008 were enrolled in this retrospective study. The inclusion criteria were as follows: verified carcinoma of the colon or the rectum, stage III (any T, N1 or N2, M0) disease by operation and pathology (according to the 1997 revision of the International Union Against Cancer tumor-node-metastasis \[TNM\] staging system); no prior cancer therapy; no portal vein thrombosis; performance status tolerated HAIC and systemic chemotherapy with Eastern Cooperative Oncology Group 0--2; modest hepatic and renal function; adequate bone marrow, and age 18--75 years.[@b11-ott-9-5897] Ultrasonography or computed tomography (CT) was also performed to confirm that there were no liver metastases within 6 months after operation. The exclusion criteria were as follows: anal cancer; received neoadjuvant chemotherapy or radiotherapy; recurrence, metastasis, or death within 6 months after operation; a history of other malignancies.

According to postoperative adjuvant chemotherapy modality, these patients were assigned to two groups: combined therapy group (patients received two cycles of HAIC plus four cycles of systemic chemotherapy) and monotherapy group (patients received six cycles of systemic chemotherapy alone).

This study was conducted in accordance with the principles of the Declaration of Helsinki and "Good Clinical Practice" guidelines. A written informed consent was obtained from all patients. Approval of the study was obtained from the institutional research ethics committee of First People's Hospital affiliated to Huzhou University Medical College.

Chemotherapy administration
---------------------------

Patients received two cycles of HAIC followed by four cycles of systemic chemotherapy (combined therapy) or six cycles of systemic chemotherapy alone (monotherapy). The HAIC regimen consisted of HAI of OXA (85 mg/m^2^) on day 1 and 5-FU (2,400 mg/m^2^) on days 2 and 3 followed by a vein infusion of FA (200 mg/m^2^) as a 2-hour infusion on days 2 and 3. After local anesthetic administration, a catheter was inserted through the right femoral artery using the Seldinger method. Arteriography of the celiac trunk was performed to reveal the hepatic arterial anatomy. The tip of the catheter was placed at the common hepatic artery or proper hepatic artery. The other end of the catheter was properly fixed and connected to the injection port of a micropump. The catheter was removed after infusion. The systemic chemotherapy regimen consisted of a 2-hour infusion of OXA (85 mg/m^2^) on day 1 followed by FA (200 mg/m^2^) as a 2-hour infusion on days 2 and 3, and by 5-FU (2,400 mg/m^2^) as a 48-hour infusion.

This study prophylactically used 5-HT3-receptor antagonist granisetron (8 mg) iv for antiemetic treatment, and administered dexamethasone (5 mg) iv prior to the application of OXA and also during 5-FU infusion. The patients received treatment every 4 weeks. Treatment was continued for six cycles in the case of clinical response or until the disease progression, unacceptable toxicity/complication, or in accordance with patient's choice.

Assessment and follow-up
------------------------

Complication and toxicity were analyzed according to medical records. Patients were followed up until the last follow-up or death. They were assessed every 2 weeks during treatment, every month during the first postoperative year, and then every 3 months thereafter. The baseline assessment also involved a medical history taking, physical examination, biological tests, measurement of the carcinoembryonic antigen (CEA) level, chest CT, and abdominal ultrasonography or CT. If recurrence or metastasis was found, they would be followed up every month and be treated in the following time periods. The diagnosis of recurrence or metastasis was made on the basis of imaging and, if necessary, cytological analysis or biopsy. A rise in CEA level alone was not accepted as evidence of relapse. The patients who were diagnosed with recurrence or metastasis would receive chemotherapy, radiofrequency ablation, or undergo surgery.

Statistical analysis
--------------------

All measurements were expressed as mean ± standard deviation. Statistical analyses were performed using the two-sample *t*-test and adjusted chi-square test for the two groups. The exact chi-square test was also used if the individual cell size was less than five counts. Ridit analysis was used to compare the distributions of ranked data. Long-term survival was analyzed using the Kaplan--Meier method, and survival curves were compared by the log-rank test. *P*-value \<0.05 was considered to be statistically significant.

Results
=======

Patient characteristics
-----------------------

Patient characteristics are shown in [Table 1](#t1-ott-9-5897){ref-type="table"}. There was no significant difference between the two groups in terms of sex, age, location of tumor, T-stage of tumor, N-stage of tumor, tumor pathology, tumor size, and serum CEA level.

Five-year disease-free survival
-------------------------------

At the time of analysis, 65 patients in the monotherapy group had relapsed or died, as compared with 53 patients in the combined therapy group. The hazard ratio for recurrence in the monotherapy group, as compared with the combined therapy group, was 1.61 (95% confidence interval, 1.06--2.52). The probability of disease-free survival at 5 years was 69.29% in the combined therapy group and 55.78% in the monotherapy group (*P*=0.021 by log-rank test) ([Figure 1](#f1-ott-9-5897){ref-type="fig"}).

Five-year overall survival
--------------------------

At the time of the cutoff date of analysis, 63 patients had died in the monotherapy group, as compared with 41 patients in the combined therapy group. The hazard ratio for recurrence in the monotherapy group, as compared with the combined therapy group, was 1.59 (95% confidence interval, 1.04--2.48). The probability of survival at 5 years was 70.71% in the combined therapy group and 57.14% in the monotherapy group (*P*=0.014 by log-rank test) ([Figure 2](#f2-ott-9-5897){ref-type="fig"}).

Five-year liver metastases-free survival
----------------------------------------

During the first 3 years after surgery, 28 of 140 patients in the combined therapy group and 45 of 147 patients in the monotherapy group developed liver metastases. The 5-year actuarial rate of liver metastases-free survival was 70% in the combined therapy group and 56.46% in the monotherapy group (*P*=0.019 by log-rank test) ([Figure 3](#f3-ott-9-5897){ref-type="fig"}).

Complication and toxicity
-------------------------

No treatment-related death occurred. All patients completed six cycles of monotherapy or combined therapy. All complications or toxicities were controlled by conservative treatment. Inguinal hematoma was observed in two patients from the combined therapy group and controlled by pressure bandage. No life-threatening toxicity or complication was observed. None of the patients required dose reduction.

Discussion
==========

Liver is commonly the first site of distant metastasis and the major target organ of metastasis from CRC.[@b12-ott-9-5897] Liver metastasis is the leading cause of death in CRC.[@b13-ott-9-5897] Despite undergoing radical resection of the cancer, over half of the patients with stage III CRC develop liver metastases.[@b14-ott-9-5897] Malignancy with liver metastasis plays an important role in daily oncology practice,[@b15-ott-9-5897] especially in CRC. The authors' believe that a reduction in the incidence of liver metastases may be the most effective way of reducing the likelihood of recurrence and for improving the prognosis.

In patients without liver metastasis at the time of surgery and judged by the surgeon to have been curatively resected, the metachronous liver metastasis occurring postoperatively is believed to originate from micrometastases present at the time of surgery.[@b16-ott-9-5897] Previously, portal vein injection of 5-FU was used at the time of surgery and during the postoperative period to prevent metachronous liver metastasis.[@b17-ott-9-5897] However, a large randomized trial showed that portal vein injection of 5-FU had no significant impact on survival.[@b18-ott-9-5897]

With regard to liver metastases from CRC, a meta-analysis of seven randomized controlled trials has suggested that HAIC of 5-FU has a significantly better RR than systemic chemotherapy.[@b4-ott-9-5897] It has been shown experimentally that liver tumors receive abundant blood supply from the hepatic artery.[@b19-ott-9-5897]--[@b21-ott-9-5897] Therefore, HAIC seems to be an attractive therapeutic modality because extraction of cytotoxic drugs from the hepatic arterial circulation via the first-pass effect can result in high local concentrations and minimal systemic toxicity.[@b22-ott-9-5897] In this study, patients in the combined therapy group were found to have a significantly better disease-free survival, overall survival, and liver metastases-free survival than those in the monotherapy group. The reason may be that HAIC eliminates the micrometastases which would later develop to metachronous liver metastasis after surgery. Moreover, no treatment-related death, life-threatening toxicity, or complication was observed in this study.

Conclusion
==========

Prophylactic adjuvant HAIC can effectively and safely prevent metachronous liver metastases and improve the prognosis of patients with stage III CRC after curative resection. However, because of the retrospective nature and the small sample size, further prospective study with large sample size is needed to confirm the results of this study.
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###### 

Patient characteristics

  Characteristics           Combined therapy (n=140)   Monotherapy (n=147)   *P*-value
  ------------------------- -------------------------- --------------------- -----------
  Sex                                                                        0.5668
   Male                     83                         92                    
   Female                   57                         55                    
  Location                                                                   0.6685
   Colon                    89                         97                    
   Rectum                   51                         50                    
  T-stage of cancer                                                          0.2302
   T1                       26                         32                    
   T2                       28                         36                    
   T3                       59                         55                    
   T4                       27                         24                    
  N-stage of cancer                                                          0.2925
   N1                       82                         95                    
   N2                       58                         52                    
  Pathology                                                                  0.8821
   Well                     21                         25                    
   Moderately               92                         90                    
   Poorly                   21                         22                    
   Mucinous                 6                          10                    
  Age (years)               64.3±14.2                  65.2±16.6             0.6228
  Tumor size (mm)           48.3±26.2                  54.2±28.9             0.0715
  Serum CEA level (ng/mL)   15.7±12.9                  18.6±13.2             0.0610
  Lost to follow-up         0                          0                     --

**Note:** Data presented as n or mean ± standard deviation.

**Abbreviation:** CEA, carcinoembryonic antigen.
